

Table of Contents

- Slides 2-36: Alzheimer's Disease Clinical Research Presentation
- Slides 37- 62: Ethical Issues in Surrogate-Based Research Presentation

Alzheimer's Disease Clinical Research

**Dr. David Knopman
Professor and Consultant in Neurology
Mayo Clinic, Rochester, Minnesota**

2

•David Knopman is a 1972 graduate of Dartmouth College, a 1973 graduate of Dartmouth Medical School and a 1975 graduate of the University of Minnesota Medical School. He did his internship at Hennepin County Medical Center, Minneapolis, a Neurology residency at the University of Minnesota and a fellowship in Behavioral Neurology at Hennepin County Medical Center and the University of Minnesota. He was a faculty member at the University of Minnesota from 1980 to 2000. He joined the Department of Neurology at the Mayo Clinic Rochester Minnesota in 2000, where he is currently Professor of Neurology, Mayo Clinic College of Medicine, a Consultant in Neurology at the Mayo Clinic, and a co-investigator in the Mayo Alzheimer's Disease Research Center. His research and clinical interests have been in dementing illnesses. He is an author on over 100 articles on various topics in dementia. He is an Associate Editor of *Neurology* as of January 2007. He was the senior author on the 2001 AAN Practice Parameter on the Diagnosis of Dementia.

Outline

- What do we know about Alzheimer's Disease and its treatment?
- What types of Alzheimer's Disease research are needed?
- Why are Alzheimer's Disease patients needed in clinical research?

What Do We Know about Alzheimer's Disease and its Treatment?

Dementia and Alzheimer's Disease

- **Dementia**: cognitive decline compared to previous levels, enough to cause loss of independence
- **Alzheimer's Disease** is the most common cause of dementia
 - Gradual onset and progression
 - Poor short-term memory, with impairment in at least one other cognitive area
 - No evidence of stroke, Parkinson's, other neurological diseases

5

Dementia can be caused by multiple diseases. Alzheimer's disease is the most common disease that causes dementia. There are other diseases that we won't talk about here that also cause dementia such as cerebrovascular disease (vascular dementia) and Lewy Body disease (associated with Parkinson's disease) as well as the frontotemporal dementias. Mild cognitive impairment is the term that describes the grey zone between normal mental function and early dementia.

Symptoms of Alzheimer's Disease

- Forgetfulness: for recent events, conversations, names
- Spatial disorientation: driving errors, getting lost, misplacing items
- Language problems: word-finding, repeats self in conversation
- Impaired judgment/reasoning: unable to handle money, unable to operate appliances, equipment
- Personality changes: social withdrawal, loss of initiative, depression, short-tempered, suspicious

From AHCP, 1996 ⁶

Memory loss - actually a difficulty with learning new things - is usually the principal symptom in Alzheimer's. The symptoms in the other cognitive domains may be equally challenging to deal with, but they are more variable from person to person with Alzheimer's.

How Alzheimer's Disease is Diagnosed


- A patient is brought to a physician, usually by a family member.
- Ideally, a physician would do:
 - Thorough medical history
 - Obtain details of duration and nature of cognitive difficulties
 - Perform mental status exam and neurological exam
 - Review CT or MR of brain
 - Check a few selected blood tests
 - Order detailed neuropsychological testing if circumstances require

How Common is Alzheimer's Disease?

- Alzheimer's disease becomes more common after the age of 65
- The number of people affected with Alzheimer's disease doubles every 5 years after the age of 65
- By age 85, about 40% of the population have Alzheimer's disease

Source: Alzheimer's Association ⁸

Alzheimer's is largely but not exclusively a disease of the elderly. It does occur in people under age 65, however.



This slide shows the natural history of Alzheimer's. There is a considerable time period between the onset of symptoms and diagnosis. If we had a way of making very early diagnoses, we could theoretically begin to treat the disease earlier than we currently are able to. Now, treatment occurs during the symptomatic window. At the end of the disease, there can be a long time between when severe dementia is present and death occurs, hence the costliness of long term care. Survival in the severe stage of the disease can be several years.

Costs to Society

- Current care for 4 to 5 million Americans with Alzheimer's Disease costs \$100 billion each year
- As population ages, number of cases will grow
- By 2030 when “baby boomers” are all over 65, costs may far exceed our ability to cover them.

¹⁰
Source: Alzheimer's Association

The biggest cost from Alzheimer's is the cost of long term care. The average yearly costs are probably more than \$40,000 per person for people with Alzheimer's in nursing homes or assisted living facilities.

Current Treatments for Alzheimer's Disease

- Two classes of drugs available
 - Cholinesterase inhibitors
 - Donepezil (Aricept®)
 - Galantamine (Razadyne® - formerly Reminyl®)
 - Rivastigmine (Exelon®)
 - Glutamate modulator
 - Memantine (Namenda®)
- However, drug treatments are not very effective.
- Other supportive treatments are available but they do not change the disease course

11

There have been 4 drugs approved for the treatment of Alzheimer's Disease since 1994. The most recently approved drug was memantine, whose trade name is Namenda.

Supportive treatment refers to education of caregivers, social services like home health aids, transportation services, day care, respite care, as well as things like financial planning.

Effectiveness of Current Treatments

- The best outcome to be hoped for with current medications is the delay of worsening of symptoms.
 - Have very modest effects on average
 - The effects do not last very long
- Improvement is very rare.

12

The key issue is that the currently available drugs have very modest benefits. Therefore, there is a pressing need to develop more effective treatments.

What Types of Alzheimer's Disease Research Are Needed?

Main Goals of Alzheimer's Disease Research

- **Goal 1:** To gain more **knowledge** about Alzheimer's Disease (with the hope the knowledge will lead to future treatments).
- **Goal 2:** To **test potential treatments** to see if they work.

Of course, some research studies will have both goals.

Research Goal 1: To Gain More Knowledge About Alzheimer's Disease

- This type of research...
 - Creates knowledge about the disease
 - Has burdens and risks for participants
 - But does not offer any direct potential benefit to the participants

15

Drug trials are more than just taking a drug. There are various assessment procedures that are necessary to see if the drug is working, and also to see how it works. Researchers and regulators at the US FDA have become more interested in understanding how the drug affects the brain and the fluid that surrounds the brain (called spinal fluid). Thus, there is an increasing emphasis on doing brain scans and measuring things in the spinal fluid during the course of the taking of medications in a study.

**Research Goal 1: To Gain More Knowledge
About Alzheimer's Disease (continued)**

- This type of research is often included in larger studies that test treatments.
- Examples of procedures used for this type of research:
 - Brain scans
 - Lumbar punctures
 - Genetic testing

One Detailed Example: Lumbar Punctures

- Overview
 - Used to study fluid surrounding brain in patients with Alzheimer's Disease
 - Long needle inserted through lower back into the spinal canal
 - Patients given numbing medicine, but may experience small amount of pain
- Benefits
 - Provide view of brain chemistry not obtainable any other way
 - No direct benefit to subject but may lead to better understanding of Alzheimer's Disease to help future patients

Lumbar punctures are generally regarded as safe, and well tolerated, especially in middle aged and older individuals.

Lumbar Punctures, continued

- Risks
 - About 5% of patients will get headaches that go away with Tylenol (or other pain reliever)
 - 1% will get a severe headache that requires inserting a needle into the back again
 - Virtually no chance of any serious neurological disability
- Discomforts
 - Pain during the procedure, though not much worse than blood drawing
- [Ultimately, a safe procedure with minor discomfort, and rare severe headache]

18

Headaches are the only common complication. They often are just a day or two, but if they are persistent, they can be effectively treated.

Other Examples of Research Procedures to Create Knowledge

- Brain scans
- Blood tests, including genetic testing
- Others

Research Goal 2: To Test Potential Treatments to See if They Work

- Treatments need to be rigorously tested so that...
 - Only truly effective treatments are used widely
 - Safety of treatments is ensured
- To avoid bias, most potential treatments are usually tested using
 - Placebo controls
 - Randomization
 - Blinding

20

Placebo controls – Persons who enroll in a clinical trial are assigned to either the experimental intervention group or the control group. The control group receives inactive intervention or an inactive drug (placebo) in such a way that the subjects do not know what they are receiving. This is done to better see the effectiveness of the new drug or treatment and gives researchers a comparison group (those on the placebo).

Randomization – Whether a subject is assigned to the control group or the experimental treatment group is decided randomly. This process is like a coin toss that is done by computer. During clinical trials, no one likely knows which therapy is better, and randomization assures that treatment selection will be free of any preference a physician may have.

Blinding - “Blinding” helps ensure that bias doesn’t distort the conduct of a trial or the interpretation of its results. A double-blind trial means that neither the participant nor the research team knows during the trial which participants receive the experimental treatment. Only the study pharmacist will know who receives which pill. The patient will usually find out what he or she received after the trial.

Research Goal 2: To Test Potential Treatments to See if They Work (cont.)

- This type of research involves...
 - Risks and burdens to participants.
 - Participants could possibly benefit, if the experimental treatment does work.
 - Essentially an experiment to see if a proposed treatment would work for people with Alzheimer's Disease in general.

Potential Treatment Studies

- We'll look at different types of research at different stages:
 - New Drugs
 - Vaccines
 - Gene Transfer Therapy

Clinical Drug Development

- It takes 15 years on average for an experimental drug to progress from laboratory to clinics.
- Only 5 in 5,000 (0.1%) compounds that enter preclinical testing make it to human testing.
- Only 1 of those five is approved for sale.

Clinical Phases of a New Drug

Laboratory Testing	Phase I	Phase II	Phase III	FDA Approval
<p>Laboratory and animal studies conducted to show biological activity of the compound against the targeted disease.</p> <p>Compound is evaluated for safety.</p>	<p>Determine safe dosage & range.</p> <p>Identify side effects.</p>	<p>Determine effectiveness.</p> <p>Further evaluate safety.</p>	<p>Confirm drug's effectiveness.</p> <p>Monitor side effects. Compare it to commonly used treatments.</p> <p>Collect information that will allow the experimental drug or treatment to be used safely.</p>	
<p>•Some Phases may be combined</p>				

24

New Drugs in Clinical Trials

- Benefits
 - May benefit patient eventually if the drug is proven to be safe and effective
- Risks
 - Drug may not work
 - Unexpected side effects are bound to occur with a new drug
 - Some side effects could be serious

25

Participation in a clinical trial requires a that the patient take on some risks with only a remote chance that the test drug will actually work as hoped. Yet, there is no way that progress will be made unless patients participate and accept some risks, ranging from no benefits to actual side effects.

AN-1792 Vaccine Study

- Overview
 - Based on exciting work in mice, researchers proposed to immunize Alzheimer patients with the “Alzheimer protein” known as amyloid-beta peptide
- Potential Benefits
 - About 350 patients were recruited in 2001
 - 80% of patients were to receive active vaccine
 - Only 25% of those were expected to have the vaccine “take”
 - 20% to receive placebo

26

A study in mice genetically engineered to have something like Alzheimer’s disease, published in 1999, showed dramatic reductions in the amount of Alzheimer brain pathology following a vaccination at middle age (for the mouse). Early but small safety studies in humans showed no serious safety concerns. Therefore a larger study was launched.

AN-1792 Vaccine Study: Outcome

- Three months into the study, patients began to show up with encephalitis (brain inflammation)
- Eventually 18 (6%) patients affected
- Study was halted
- 6 of 18 (33%) suffered permanent substantial worsening of their conditions

27

A sobering reminder of the risks. Some might say, “well it was only 18 people. This is a bad disease. The risk is worth it.” But other people may not accept that logic, and may take the seriousness of the side effects as a criticism of the researchers for not predicting the risk in a smaller study. However, predicting side effects is a very difficult task.

AN-1792 Vaccine Study

- Some analyses suggested therapy might have been beneficial
- Did risks to 6% justify halting trial?
- Was study begun prematurely, before sufficient safety data was available?

28

The overall results from all eligible subjects did not show a substantial benefit of the vaccine. However, it appeared that there were some improvements on some of the more sophisticated memory measures. One troubling issue was that there was a significant change on the brain scans of people who were vaccinated, and that was that their brains got smaller! The significance of the brain scan findings is unknown.

Gene Transfer Therapy in Alzheimer's Disease

- Overview

- Rationale was that Nerve Growth Factor (NGF) might promote survival of key nerve cells in brain damaged by Alzheimer's
- Genetic material (DNA containing NGF gene) was inserted into the brains of Alzheimer's patients using brain surgery
- A Phase I study was performed in 8 patients with Alzheimer's disease
- Purpose was to test its safety in just a few people before moving on to larger studies

29

There was a theoretical basis for carrying out this trial. It was known from research studies in animals and humans that NGF promoted the growth of nerve cells known to be damaged in Alzheimer's disease. However, it was not clearly known whether this mechanism actually had anything to do with the cause of Alzheimer's or contributed in any material way to the progression of the disease.

Gene Transfer Therapy in Alzheimer's Disease

- **Outcome**
 - 2 (25%) subjects had bleeding during surgery; thereafter general anesthesia used...one died 5 weeks after the operation
 - Other 6 (75%) subjects:
 - No long term adverse effects thus far
 - PET scans said to show improvement (increased activity) in brain metabolism
- **Risks**
 - Surgical complications
 - Unknown effects of gene over-expression

30

Phase I studies are critical to get some idea of safety of the therapy, but they cannot usually tell anything about whether therapy works. A trial with 6 subjects and no control group simply cannot tell us anything about whether the therapy worked.

**Why Are Alzheimer's
Disease Patients Needed
in Clinical Research?**

Why Are Alzheimer's Disease Patients Needed in Clinical Research?

- Clearly, current therapies are inadequate.
- New treatments can only come from more research.
- Potential new treatments for Alzheimer's Disease must be tested on actual people with Alzheimer's Disease, because that is the only way to know if it works and is safe.

32

No matter how much testing is done on laboratory animals, Alzheimer's is fundamentally a human disease, and drugs need to be tested in humans to see if they work and to make sure they are safe for humans.

How Are Alzheimer's Disease Patients Currently Included in Clinical Research?

- Family members are almost always the ones who seek out participation for the patient
- Research is almost always done in academic research centers
- Patients usually have a more passive role...Some patients may have expressed interest in research

33

Participation in drug trials in Alzheimer's involves a partnership between the research team, the patient and a study partner (a fancy word that usually means either a spouse or an adult child). In my experience, it is very rare for a patient him or herself to initiate contact with physicians for Alzheimer's. Therefore it is the family who does so.

How AD patients are currently enrolled...

- Study is explained to both the patient and the family member, and the consent form is reviewed in detail
- Research staff conducting informed consent must make a determination whether the patient is able to provide own consent
 - If patient's mental capacity is reduced, surrogate's (the family member) consent for patient is sought along with "assent" from the patient
- Since all AD studies require active involvement of surrogate, consent must always be obtained simultaneously from surrogate.

34

Initial contact could either be from surrogate, less likely patient, in response to an advertisement or announcement of a trial, or from study personnel reviewing records of persons previously seen at the research center who had expressed interest in future research.

Current Alzheimer's Disease Research Participants Are...

- About 75 years old on average
- Mostly able to bathe and dress themselves
- Able to prepare simple meals and do simple chores
- Able to communicate conversationally in a way that might not appear abnormal to the casual observer
- In need of traveling with a companion
- But majority who participate, even if mild-to-moderate severity Alzheimer's Disease, cannot give their own informed consent

The Ethical Dilemma

- Alzheimer's is a common disorder that lacks an effective treatment
- Development of new therapies requires patient volunteers
- Participation in research involves a lot of time, some risks and possibly discomfort
- Alzheimer's Disease makes it impossible for most patients to give their own informed consent
- How should informed consent be obtained?

Ethical Issues in Surrogate-Based Research

Paul S. Appelbaum, MD
Dollard Professor of Psychiatry, Medicine, and Law
Columbia University, New York

37

•**PAUL S. APPELBAUM, M.D.** is the Elizabeth K. Dollard Professor of Psychiatry, Medicine, and Law, and Director, Division of Psychiatry, Law, and Ethics, Department of Psychiatry, College of Physicians and Surgeons of Columbia University. He was previously A.F. Zeleznik Distinguished Professor of Psychiatry; Chairman of the Department of Psychiatry; and Director of the Law and Psychiatry Program at the University of Massachusetts Medical School. He is the author of many articles and books on law and ethics in clinical practice and research. Dr. Appelbaum is a Past President of the American Psychiatric Association, the American Academy of Psychiatry and the Law, and the Massachusetts Psychiatric Society, and served as Chair of the Council on Psychiatry and Law for the American Psychiatric Association. He has been elected to the Institute of Medicine of the National Academy of Sciences. Dr. Appelbaum is a graduate of Columbia College, received his M.D. from Harvard Medical School, and completed his residency in psychiatry at the Massachusetts Mental Health Center/Harvard Medical School in Boston.

Why Is Surrogate-Based Research Being Discussed?

- Much remains unknown about dementias
- For many studies, only people with dementia can be subjects
- Unless someone else (i.e., a surrogate) can give consent for them, this kind of research cannot take place
- But, what are the ethics of surrogate consent for research?

Outline

- How is clinical research currently regulated in the U.S.?
- How is surrogate-based clinical research currently regulated?
- Ethical questions that still need answers.

How Is Clinical Research Currently Regulated in The United States?

History of Research Ethics

- Until after World War II, little attention was paid to the ethics of research
 - Amount of research was small
 - Physician/researchers generally trusted not to harm their subjects
- Trial of Nazi doctors at Nuremberg began to call attention to need for focus on research ethics

In order to better understand how we regulate research now, we need to understand the history of how the current system came about.

Scandals Turn the Tide

- 1963 – Jewish Chronic Disease Hospital
 - Injection of cancer cells into elderly patients
- 1966 – Willowbrook State School
 - Injection of virus that causes hepatitis into mentally retarded children
- 1972 – Tuskegee
 - Long-term follow-up of African-American men with syphilis without providing treatment

42

Jewish Chronic Disease Hospital case – Researchers looking to study the body's immunologic response to cancer injected cancer cells from other people into elder, debilitated or demented patients.

Willowbrook State School case – In a facility for children with mental retardation, where conditions were abysmal and almost all residents ultimately developed hepatitis (i.e., inflammation of the liver), researchers approached parents of children prior to admission to ask for consent to deliberately infect their children with hepatitis, to study the disease and its treatment. At times, the only unit at the facility with open beds was the research unit, meaning that the only way desperate parents could get their children admitted was to agree to the research study.

Tuskegee case – In 1932, the US Public Health Service began a long-term study of 200 black men with syphilis (i.e., an infectious, sexually transmitted disease) to observe the natural progression of the disease. Subjects were not told their diagnosis and were blocked from obtaining treatment, even when cheap effective treatment with penicillin became available in 1947. Many of the subjects died from syphilis, 40 wives were infected, and 19 children were born with congenital syphilis. The study was terminated when a physician/whistle-blower went to the press with the story.

These episodes and others led to progressively increasing pressure for closer oversight of medical research.

Principles Underlying Current Regulation of Research

- 1991 Federal Regulations govern most research in the U.S., based on:
 - Respect for persons
 - Respect autonomy, protect diminished autonomy
 - Beneficence
 - Do no harm, maximize good that is done
 - Justice
 - Fair distribution of burdens and benefits of research

Embodied in well-known statement of ethical principles, the Belmont Report, issued in 1979 by The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.

Oversight of Research

- Food and Drug Administration (FDA)
- Institutional Review Board (IRB)
- Sometimes, there is additional oversight depending on type of research:
 - Pharmaceutical companies
 - Coordinating sites in multi-site research
 - Data Safety Monitoring Boards (DSMBs)

44

Pharmaceutical companies conduct site visits to ensure compliance with research protocols.

Coordinating sites in multi-site research includes site visits and periodic retraining of research staff.

Data Safety Monitoring Boards (DSMBs) conduct periodic reviews of safety (e.g., side effects) and data to determine if the study should be modified or stopped.

The role of the FDA is explained on slide 48.

The role of the IRB is explained on slide 49.

The Role of The Food and Drug Administration (FDA)

- Primary role: Determine whether medical treatments are effective and safe enough for marketing
- Oversees clinical trials so that
 - Participants are protected from unreasonable risks in clinical trials.
 - Participants are given reliable and accurate information about whether to participate or not in the clinical trial.
- Performs inspections of clinical trial study sites.

45

The Food and Drug Administration's job is to make sure medical treatments are safe and effective for people to use.

The FDA works to protect participants in clinical trials and to ensure that people have reliable information as they decide whether to join a clinical trial.

The federal government has regulations and guidelines for clinical research to protect participants from unreasonable risks.

The FDA does not develop new therapies, or conduct the clinical trials to demonstrate safety and effectiveness.

FDA staff members meet with researchers, and perform inspections of clinical trial study sites to protect the rights of participants and to verify the quality and integrity of the data.

Current Oversight of Research: Institutional Review Boards (IRBs)

- IRBs are ethics committees that review all research involving human subjects
 - Every research institute has a local IRB
 - Researchers must submit plans for research to IRBs in their institutions
 - IRBs can approve, modify or disapprove proposals
 - IRBs must include at least 5 people of varying backgrounds

46

The 5 people must be of varying backgrounds, including at least one non-scientist and one person not affiliated with the institution.

Must have IRB approval before proceeding with research.

IRBs Make Their Decisions Based on Laws that Require...

- Risks to subjects are minimized
- Risks to subjects are reasonable
- Selection of subjects is fair
- Informed consent will be sought and documented in some way
- Safety will be monitored and privacy protected
- **Additional protections can be required for vulnerable groups**

47

Reasonable risk is measured in part in relation to anticipated benefits and importance of knowledge

Vulnerable groups include children, prisoners, pregnant women, mentally disabled people (including those with dementia), and economically or educationally disadvantaged people.

Basic Elements of Informed Consent Disclosure

- Purpose and nature of research
- Foreseeable risks and discomforts
- Reasonably expected benefits to subject or others
- Alternatives available to subjects
- Extent of confidentiality of information
- Availability of compensation for injury
- Person to contact in case of injury
- Right to refuse to participate or to withdraw

48

This is the minimum that researchers have to tell people who they are recruiting into their studies before getting their consent.

How Is Surrogate-Based Clinical Research (SBR) Currently Regulated?

Current Practices and Issues

- Determining competence
- Degrees of impairment and the ability to consent
- What do the laws and regulations currently say?

Determining Competence

- People with dementia are considered incompetent only if they have significant impairment of one or more of the following abilities:
 - Understanding, i.e., comprehending information
 - Appreciation, i.e., recognizing the implications of their choices
 - Reasoning
 - Making a choice

51

Studies suggest that most people with very mild dementia can still meet these standards for making their own decisions. But as severity increases, the percentage of competent people declines. Most people with moderate dementia are no longer capable of making their own decisions and a substitute decision maker is needed.

Degrees of Impairment and the Ability to Consent

- Various levels of ability exist among those with Alzheimer's Disease – Recall the video presentation
 - Early stage – Just diagnosed and still independent and probably competent
 - Mild – Can Still communicate, live at home, but has poor judgment. Is somewhat independent but probably not competent
 - More severe – Uncommunicative, bedridden, etc. Dependent and clearly incompetent
- The point is that "incapable of consent" captures a wide range of people
 - Some are able to cooperate and talk with caregivers and researchers, yet still be too impaired to give own consent
 - Some are unable to cooperate at all

What Do the Laws and Regulations Currently Say?

- Currently, when an adult lacks the capacity to give informed consent for research...
 - The federal regulations allow someone else—a “legally authorized representative” (**LAR**) to consent on their behalf
 - **But LAR is not defined; it is left to the states and local governments to define.**
 - **Few states have made clear who can be LAR.**
- In some studies, surrogate consent is obtained from family members, but the current legal foundation for this practice is weak in most states
- Thus, in most places, surrogate consent represents a “gray zone” of law
- Even in states that have surrogate consent laws, IRBs still have the authority to approve or deny permission for the research or use of surrogates

LAR functions as the surrogate decision-maker

- Disclosure would be made to the LAR and the LAR would make the decision.
- Patient would also be told as much as he/she could understand about the study, and asked if he/she agrees to participate (“assent” or “dissent”)
- **Best candidates to be LAR are family members – spouse, adult child, parent, sibling, etc.**

54

There are advantages to using family members as the LAR, but some disadvantages as well.

Advantages:

- Family members are likely to be readily available;
- They are presumed to care about the interests of the impaired person;
- Family members are most likely to know what the impaired person himself or herself might have wanted to do in this situation;
- Appointment of alternative decision makers, such as legal guardians, is likely to be time-consuming and costly, and will only rarely be pursued.

Disadvantages:

- Family members are likely to have no particular background in science/medicine—may have a hard time understanding what the study is about, and the risks and benefits of the patient’s participation
- There could be a conflict between the family member’s interests and the patient’s interests, e.g., if a monetary incentive is being offered for participation

But on balance, family members are the best candidates for the role.

Should a patient object to continuing in a study, even if he/she were not considered competent to decide on participation in the first place, the person’s participation would be ended. If treatment were required, it would be provided outside of a research project (i.e., ordinary clinical care).

Would advance directives solve the problem?

- Medical Advance Directives
 - Durable Powers of Attorney (POA) for healthcare
 - Living Wills for healthcare
 - PROBLEM: Research and treatment are different.

- Research Advance Directives
 - PROBLEM: Not enough people use them.

55

Advance directives allow people to make choices about their medical care in the future, should they become unable to make decisions for themselves at the time.

They may take the form of:

- Durable Powers of Attorney for Healthcare – allow appointment of someone else to make medical decisions in the event of future incapacity (e.g., a spouse); or
- Living wills for healthcare – in which the person him/herself makes an advance decision (e.g., no CPR); or
- Advance directives that combine both.

In principle, similar advance directives could be developed to consent to research. But there are several problems with this approach:

- Currently, no laws provide for it;
- Difficult to anticipate the types of studies for which one might be eligible;
- Unlikely that many people will complete them.

Ethical Questions That Need Answers

Main Policy Questions

- Should family members be allowed to give surrogate consent (that is to act as the LAR)?
- If so, for what types of research?

Reasons in Favor of Surrogate Consent for Research

- Importance of advancing knowledge about disorders that impair thinking, such as Alzheimer's Disease
- If potential research subjects designate a surrogate decision maker in advance, abiding by that person's judgment respects the subject's autonomous choice
- If families are already allowed to make life/death treatment decisions for incapacitated loved ones, they should be given authority for research consent too.

58

These arguments are based on the principles for regulation of research that we discussed earlier:

Advancing knowledge is an aspect of beneficence, though towards third parties and not the patient/subject.

Respecting autonomous choice is a reflection of respect for persons.

Reasons Against Surrogate Consent for Research

- Someone else does not have the right to make a decision that exposes a person to risk...
 - When there is no compensating benefit (e.g., physiologic studies)
 - When benefit is unproven (e.g., clinical trials)
- Incompetent subjects lack the ability to protect themselves if things go wrong

59

Example of study without prospect of benefit: fMRI (i.e., brain scan) study in a person with Alzheimer's Disease.

Example of study where benefit is unproven: clinical trial of new medication to see if it slows down the progression of Alzheimer's Disease.

Example: A person too confused to recognize that the headache they are suffering may relate to the study in which they are enrolled may not tell the researchers, who may not know about the adverse effect until permanent harm has occurred.

Questions To Be Resolved Regarding Surrogate-Based Research - 1

- Should we let a family member or someone else make the decision for someone who is too impaired to make a decision for themselves about entering a research project?
 - If we say no, what is the likely impact on research in dementia and other disorders that affect the mind?
 - If we say yes, how can we best protect the autonomy and safety of our research subjects?

Questions To Be Resolved Regarding Surrogate-Based Research - 2

- If we say surrogate consent can be permissible how should we limit, if at all, the scope of the authority we are willing to give surrogates?
 - It's permissible but only if the subject is likely to have some benefit in participation from participation in the study?
 - It's allowed for minimal risk research only?
 - Only if the patient had an advance directive specifically for research participation?

61

What are the consequences of each of these limitations?

- If limited to research with some prospect of benefit to subjects, studies of the basic mechanisms of illnesses like Alzheimer's Disease would be excluded (e.g., imaging studies of the brain), thus slowing down the development of knowledge that might be needed to develop effective treatments. And many such studies only represent a small degree of risk to subjects.
- If limited to minimal risk research, among the studies excluded would likely be many studies of new treatments for Alzheimer's Disease, since the side-effects associated with many new medications are usually considered to represent more than minimal risk.
- If we require that subjects have designated a surrogate decision maker in advance, the reality is almost certainly that few people will do this, meaning very few additional subjects would be available for research studies.

Approximately 15% of the population has advanced directives, even though the likelihood that we will all need a directive for medical treatment at some point is very high. What percentage will have one for research purposes? Not a solution to the overall problem.